Novartis AG ADR (NVS)vsOwlet Inc (OWLT)
NVS
Novartis AG ADR
$154.44
-0.15%
HEALTHCARE · Cap: $291.32B
OWLT
Owlet Inc
$5.44
-1.09%
HEALTHCARE · Cap: $150.26M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 52854% more annual revenue ($56.69B vs $107.06M). NVS leads profitability with a 22.5% profit margin vs -43.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
OWLT
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-66.5%
Fair Value
$92.73
Current Price
$154.44
$61.71 premium
Intrinsic value data unavailable for OWLT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
No standout strengths identified
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -526.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : OWLT
OWLT has a balanced fundamental profile.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : OWLT
The primary concerns for OWLT are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a value stock while OWLT is a turnaround play — different risk/reward profiles.
OWLT carries more volatility with a beta of 1.84 — expect wider price swings.
OWLT is growing revenue faster at 6.4% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 28/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Owlet Inc
HEALTHCARE · MEDICAL DEVICES · USA
Owlet Inc. is a leading innovator in infant health technology, dedicated to enhancing the safety and wellness of newborns through its state-of-the-art monitoring solutions. The company's flagship product, the Owlet Smart Sock, employs advanced pulse oximetry to provide parents with real-time insights into their infants' heart rates and oxygen levels via mobile devices. With growing demand for pediatric health monitoring solutions, Owlet is well-positioned to expand its product offerings and fortify its market presence. The company's focus on delivering actionable health information and improving pediatric care aligns with institutional investors' interests in the dynamic health technology sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?